Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).

NCT Number	NCT06992128
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Weifang People's Hospital, Shenzhen Second People's Hospital, The Affiliated Hospital of Qingdao University, Affiliated Hospital of Nantong University, The First Affiliated Hospital of Bengbu Medical University, The Second Affiliated Hospital of Dalian Medical University, Affiliated Hospital of North Sichuan Medical College, Changzhi Medical College, North China University of Science and Technology, Tianjin Hospital of ITCWM-Nankai Hospital, Baoding First Central Hospital
Conditions	Primary Immune Thrombocytopenia (ITP)
Enrollment	129 participants
Start Date	2025-05-22
Primary Completion	2028-01-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-28